



# Prípad SD-IAP 610


P Talarčík  
Cytopathos


**Vek 55 rokov, muž**


**Klinika: silné bolesti 2-3 týždne v lumbálnej oblasti bilat., t.č. dyspnoe, liečil sa na LIS**


**Zobrazovacie vyš.: difúzny tumorózny proces v retroperitoneu siahajúci až do mediastína**

**Makro: excízia tumoru retroperitonea, 3x2x1 cm, lipomatózneho vzhľadu**









# Imunohistochémia:


Negativita: LCA, CD20, CD3,  
AE1/AE3, CK8/18, S100

**Imunohistochémia:**


**Pozitivita: EMA**

**Negativita: CD30**


**EMA**




**CD 56**




**Bcl-2**




**CD43**



**CD138**



**Ki67**






**MUM-1**



200  $\mu\text{m}$

**C-myc**



## **Imunohistochémia:**

**Negativita:** CD2, CD3, CD4, CD5,  
CD7, CD11c, CD13, CD20, BOB-  
1, TdT, CD79a, PAX5, HHV-8,  
cyklin-D1, LMO2, cytokeratíny,  
S100, melan-A, EBV-LMP1,  
ALK1

**Pozitivita:** CD138, MUM-1 ,  
C-myc, bcl-2, CD56, CD43

?

# Plazmablastický lymfóm retroperitonea.

Dif.dg.:

Plasmacytoid MM, poorly differentiated carcinomas, plasmacytoid ca, sarkomatoid GIST, plasmablastic EP, Burkitt's/like lymphoma, ALCL, extracavitary solid PEL HHV8+, DLBCL NOS, EBV+ DLBCL of elderly, ALK+ DLBCL, DLBCL ACI, HHV8+ LBCL,

## Genetika:

1. Prestavba bcl-2, resp. t/14,18/-  
bcl-2/IgH
2. Prestavba c-myc, resp. t/8,14/-  
c-myc/IgH

# Double-hit plasmablastic lymphoma?

# Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis

Anuradha Kanungo, L Jeffrey Medeiros, Lynne V Abruzzo and Pei Lin

*Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA*

Morphologically, nine neoplasms had features of Burkitt or atypical Burkitt lymphoma/leukemia and three were diffuse large B-cell lymphoma with high-grade cytologic features.

The remaining two cases were plasmablastic myeloma and low-grade B-cell lymphoma, respectively. All cases expressed BCL-2.

Anamnéza.

Pacient od 2002 liečený  
ako B-ALL.

# PB – klinickopatologické skupiny.

- HIV +
- HIV -
- Potransplantačne
- Plazmablastická transformácia
- Pediatrická skupina

# Plasmablastic Transformation of Low-grade B-cell Lymphomas Report on 6 Cases

Daniel Martinez, MD,\* Alexandra Valera, BSc,\* Nhora Silva Perez, MD,†

Luz Fernanda Sua Villegas, MD,† Blanca Gonzalez-Farre, MD,\* Carla Sole, BSc,\*

Eva Gine, MD, PhD,\* Armando Lopez-Guillermo, MD, PhD,\* Gaël Rouet, PhD,\*

Salomé Martinez, MD,‡ Francesc Sant, MD,§ Krzysztof Warzocha, MD,|| Tadeusz Robak, MD,¶

Magdalena Czader, MD,# Neus Villamor, MD, PhD,\* Lluís Colomo, MD, PhD,\*

Elias Campo, MD, PhD,\* and Antonio Martinez, MD, PhD\*

## Transformation of Follicular Lymphoma to Plasmablastic Lymphoma With c-myc Gene Rearrangement

Ihsane Ouansafi, MD,<sup>1</sup> Bing He, PhD,<sup>2</sup> Cory Fraser, MD,<sup>1</sup> Kui Nie, MD,<sup>1</sup> Susan Mathew, PhD,<sup>3</sup>

Rumina Bhanji, MD,<sup>1</sup> Rana Hoda, MD,<sup>4</sup> Melissa Arabadjieff, MD,<sup>1</sup> Daniel Knowles, MD,<sup>1</sup>

Andrea Cerutti, MD,<sup>2</sup> Attilio Orazi, MD,<sup>1</sup> and Wayne Tam, MD, PhD<sup>1</sup>

**Key Words:** Follicular lymphoma; Plasmablastic lymphoma; Transformation; c-myc

DOI: 10.1309/AJCPWY1SGJ9IEADR

**Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors**

DH plasmablastic  
lymphoma

versus

DH plasmablastic  
transformation

# B-ALL/NHL 2002

MYC:4-8x MYC v

prestavbe a ziskom 3' MYC pozit. 100%

MYC/IgH/cep8:

tetrazómia chr. 8

pozit. 88%

$t(8;14)$

MYC (3-10x), zisk

IgH (3-10x) pozit.

92%

**Double-hit t/8,14/-/14,18/**

**plazmablastická  
transformácia**

**B-NHL typu**

**B-ALL s t/8,14/**

**retroperitonea.**

Dg. záver: B-NHL-typu DLBCL CD20- plazmablastový variant "double hit" IV.B št. IPI 4  
Dg. záver: B-NHL-typu DLBCL CD20- plazmablastový variant "double hit" IV.B št. IPI 4 (generalizovaná LAP, bulky v RP)  
(generalizovaná LAP, bulky v RP)

- st.p. HD melfalan+ASCT 1.2.2016
- st.p. febrilnej neutropénii so sep. Šokom, etiol. Polyrez. Kleps. Pneumonie z HK 2/2016
- St.p. 1. kúre COPP
- st.p. 1x DA EPOCH + Bortezomib 1/16 s efektom progresie ochorenia
- st.p. A2 do 55 rokov + i.t. (negat) 12/2015 s efektom progresie ochorenia
- st.p A1 fáze B-ALL/NHL 2002 nad 55rokov + i.t. profylaxia (negat.) 11/2015
- st.p. bioptizácií TU v RP 9/2015

Exitus tesne po 18.4.2016

